| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802009303018 | 200930301 | CARBOPLATIN/HOSPIRA SOL.INF 150MG/15ML VIAL ΒΤ x 1 VIAL x 15 ML (σε φιαλίδιο διαφανές) | 19.34 | 20.29 | 27.96 |
| 05/2018 | 2802009304015 | 200930401 | CARBOPLATIN/HOSPIRA SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML (σε φιαλίδιο διαφανές) | 54.91 | 57.60 | 73.27 |
For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide.
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
Toxic by ingestion. May be create toxic effect through inhalation or skin contact. May cause reproductive defects. May act as a sensitizer. ORL-RAT LD<sub>50</sub> 343 mg kg-1; SCN-RAT LD<sub>50</sub> 72 mg kg-1; IPN-MUS LD<sub>50</sub> 118 mg kg-1
1.1-2 hours
The major route of elimination of carboplatin is renal excretion.
* 16 L
* 4.4 L/h [Patients with Clcr >= 60 mL/min receiving IV infusion of 300 to 500 mg/m2]